Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Department of Pediatrics, University of California San Diego School of Medicine and Rady Children's Hospital San Diego, La Jolla, CA, USA.
- Published Article
The Journal of pediatrics
- Publication Date
Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/08/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/18672254